Ulucaköy Coşkun, Atalay İsmail Burak, Öztürk Recep, Yapar Aliekber, Karakoç Yaman
Department of Orthopaedics and Traumatology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Demetevler Mahallesi, Vatan Cad., 06200 Yenimahalle, Ankara Turkey.
Indian J Surg Oncol. 2024 Mar;15(Suppl 1):86-93. doi: 10.1007/s13193-020-01153-z. Epub 2020 Aug 1.
The aim of this study is to determine the treatment modalities and clinical characteristics of 12 patients diagnosed with giant cell tumor (GCT) of the hand and foot. The clinical findings, treatment modalities, and treatment failures of 12 patients with giant cell tumors of the hand and foot bones between 2007 and 2018 years were evaluated retrospectively. The average age at diagnosis was 29.2 ± 14.9 std. (between 16 and 62 years old), 8 males (66.6%) and 4 females (33.3%). Tumor was more frequently located in the talus, metacarpal, and metatarsal bones. The mean tumor size was 3.1 ± 1.1 cm (between 2.2 and 5.3 cm). The mean post-operative follow-up period was 76.3 ± 42.5 (between 12 and 139 months). The most of patients' (58.3%) common complaints were pain. The most commonly used surgical method was curettage + autografting (91.7%). Infection was seen in one patient after relapse surgery. Recurrence occurred in 33.3% of the patients in the first year. Only one patient was detected to have knee and lung metastases. Swelling and pain in the hand and foot should be examined for tumor lesions. When a bone lesion is detected, the giant cell tumor of the bone should be included in the differential diagnosis. Patients with giant cell tumors should be followed closely for recurrence and metastasis after treatment.
本研究的目的是确定12例被诊断为手足骨巨细胞瘤（GCT）患者的治疗方式及临床特征。回顾性评估了2007年至2018年间12例手足骨巨细胞瘤患者的临床表现、治疗方式及治疗失败情况。诊断时的平均年龄为29.2±14.9标准差（16至62岁），男性8例（66.6%），女性4例（33.3%）。肿瘤更常见于距骨、掌骨和跖骨。肿瘤平均大小为3.1±1.1厘米（2.2至5.3厘米）。术后平均随访期为76.3±42.5（12至139个月）。大多数患者（58.3%）的常见主诉是疼痛。最常用的手术方法是刮除术+自体骨移植（91.7%）。1例患者复发手术后出现感染。33.3%的患者在第一年复发。仅1例患者被检测出有膝关节和肺部转移。对于手足部肿胀和疼痛应检查是否存在肿瘤病变。当检测到骨病变时，骨巨细胞瘤应列入鉴别诊断。骨巨细胞瘤患者治疗后应密切随访有无复发和转移。
